1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Human And Animal Vaccine Adjuvants Market Size, Forecast And Trend Analysis, 2015 - 2025

Human And Animal Vaccine Adjuvants Market Size, Forecast And Trend Analysis, 2015 - 2025

  • September 2018
  • 80 pages
  • ID: 5583936
  • Format: PDF
  • Hexa Research

Summary

Table of Contents

Human And Animal Vaccine Adjuvants Market Size And Forecast, By Product Type, By Application, By Route Of Administration, By Category (Human, Animal) And Trend Analysis, 2015 - 2025

The global human and animal vaccine adjuvants market size is expected to reach at USD 1.07 billion by 2025. High prevalence of diseases and rising research activities in developing regions are anticipated to propel market growth over the forecast period.

Development and manufacturing of adjuvants is mostly carried out at established facilities in developed countries. However, transferring vaccine technologies to developing countries will help in targeting emerging diseases and will enable mass production. This factor will also ease getting regulatory approvals, as antigen and vaccines cab be manufactured locally.

Vaccine manufacturers present in developing countries play a significant role in development and manufacturing of vaccines. For instance, in 2017, Serum Institute of India produced 1.2 billion doses, making it the leading manufacturer in the world. Transferring vaccine technology to developing nations will help manufacturers develop innovative vaccines against challenging illnesses that are not a prevalent in the developed world. Furthermore, this provision presents a cost-effective alternative since labor and materials are less expensive in developing countries.

Increasing need for efficient immunization is expected to boost the demand for new human and animal vaccine adjuvants. Conventional vaccine adjuvants, such as alum is less effective against fatal diseases, therefore, key market players are focusing on introducing new and effective products. Many other adjuvants are under clinical trials and are expected to be registered in the forthcoming years. This factor is anticipated to bode well for the expansion of the global human and animal vaccine adjuvants market in near future.

For instance, CpG (TLR 9 agonist) vaccine adjuvant from InvivoGen Inc. The product is in Phase III of clinical trial. It is CD8 T cell-mediated immunity and Th1 type immunity. Others include SAPONEX, a synthetic version of QS-21, under phase III trials. It was recently approved for use in GSK’s pediatric malaria vaccine Mosquirix.

Advance form of these products are Nano particle and recombinant vector vaccine adjuvants. For instance, CaPtivant is working on development of calcium phosphate nanoparticle vaccine adjuvants. This technology helps in enhancing immune response against parasitic, bacterial, and viral antigens. Saponin-based adjuvants at different various developmental stages. Desert King International is a leading producer of food grade saponin in the world. The company supplies pure saponin extract, rich in QS-21 for pharmaceutical applications. With its Quillaja saponaria forestry operations and production facility in Chile, the company has established a robust, integrated supply chain to ensure quality extracts.

Many companies, such as Brenntag Biosector A/S, are engaged in R&D activities to develop Saponin-based adjuvants. Major players operating in the human and animal vaccine adjuvants market such as GlaxoSmithKline (GSK) plc, held major shares in U.S. and Europe markets. In October 2017, GSK received the U.S. Food and Drug Administration (FDA) approval for the sale of Shingrix for the prevention of shingles.

Some of the prominent companies in the market include Adjuvance Technologies, Inc.; Novavax, Inc.; and InvivoGen. Most companies focus on development of cancer and HIV vaccines. They are engaging in mergers and acquisitions to strengthen their position in emerging markets, such as India, China, and Mexico. For instance, in September 2015, GSK acquired Novartis Vaccine and divested its marketed oncology portfolio to Novartis India. Moreover, in July 2015, bioCSL and influenza vaccines unit of Novartis came together to form Seqirus, which is now among leading influenza vaccine companies in the world.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2018

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on